<< Return to Courses
Dr. Shannon Manzi discusses Massachusetts and federal laws pertaining to opioid deterrence and medical marijuana, reviews detection tools, and looks at the vaping crisis. The presentation was recorded at Effective Pediatric Pain Management and End of Life Care, on March 6, 2021.
At the conclusion of this educational program, learners will be able to:
- Discuss the laws surrounding opioid and medical marijuana misuse and deterrent measures in Massachusetts, and where we’re headed with the federal government.
- Describe the current tools that are available for detecting this misuse of prescription drugs.
- Describe the vaping crisis and how that actually fits into the marijuana use and the medical marijuana use.
Boston Children’s Hospital designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
This activity meets the requirements for 0.75 Risk Management Credits as proscribed by the Massachusetts Board of Registration in Medicine and defined in 243 CMR 2.06(5)(d) I. Please check your individual state licensing board requirements before claiming these credits.
Boston Children’s Hospital designates this activity for 0.75 contact hours for nurses. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Boston Children’s Hospital has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Boston Children’s Hospital adheres to all ACCME Essential Areas, Standards, and Policies. It is Boston Children’s policy that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that Boston Children’s may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
The following planners, speakers, and content reviewers, on behalf of themselves, have reported the following relevant financial relationships with any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on patients:
Shannon Manzi, PharmD : Scientific Advisory Board Member for Global Gene Corporation; Consultant at Stoke